Juliana P. Salazar

Barcelona, CT 08041, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.

Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.

Journal: International journal of molecular sciences

Published: May 05, 2026

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 11, 2025

Past and present of prostate cancer screening in the European Union.

Past and present of prostate cancer screening in the European Union.

Journal: Actas urologicas espanolas

Published: July 10, 2025

The future of prostate cancer screening in the European Union: PRAISE-U project.

The future of prostate cancer screening in the European Union: PRAISE-U project.

Journal: Actas urologicas espanolas

Published: March 29, 2025

CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

CD274 (PD-L1) Polymorphisms as Predictors of Efficacy in First-Line Platinum-Based Chemotherapy for Extensive-Stage Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: March 19, 2025

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Journal: Pharmaceutics

Published: October 07, 2024

ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.

ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer.

Journal: Pharmaceutics

Published: July 10, 2024

CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.

CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.

Journal: Diagnostics (Basel, Switzerland)

Published: April 25, 2024

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.

Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy.

Journal: International journal of molecular sciences

Published: January 03, 2024

Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients.

Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients.

Journal: Biomedicines

Published: October 23, 2023

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.

Journal: British journal of clinical pharmacology

Published: October 20, 2023

Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients.

Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn's disease patients.

Journal: The pharmacogenomics journal

Published: September 04, 2023

Showing 1-12 of 52

Last Updated: 09/26/2026